Ackman Pulls NYSE Rule Change Proposal
by Kristi Marvin on 2022-04-28 at 6:32pm

Intends to list SPARS on OTC instead

This afternoon, Pershing Square SPARC Holdings, which is the affiliate of Pershing Square Tontine Holdings (NYSE: PSTH), put out a press release stating they intend to withdraw their proposed amendment to the New York Stock Exchanges listing rules that would have allowed SPARC warrants, or “SPARs”, to trade on the NYSE.

However, the SPARC still intends to continue and be traded on the OTC market once the registration statement is approved by the SEC. This follows the Eagle team pulling Screaming Eagle’s registration statement, which was their own novel structure and bore some similarities to the SPARC.

Pershing Square noted today that, “In view of the Securities and Exchange Commission’s recently proposed rule changes and policy guidance with respect to special purpose acquisition vehicles, we understand that the approval of the NYSE rule change as currently proposed would not likely have occurred at this time.” 

If you recall, the SEC decided to go ahead with instituting proceedings on the SPARC NYSE rule change back in December. The SEC then had a maximum of 240 days from the initial publication of the proposal to issue a disapproval order, which would have ended on May 8, 2022.

Unfortunately, now is not an ideal time to put forth innovation in structures given the current regulatory climate. Subsequently, for both Ackman and the Eagle team, that meant having to pull their rule proposals at the NYSE, albeit, maybe only temporarily.

That’s because the press release also notes that the NYSE reserve’s the right to seek approval of a revised rule once the SEC puts forth its new SPAC rules.

Keep in mind that the SPARC structure still intends to issue SPARs to PSTH shareholders, regardless of whether PSTH’s outcome is a business combination or a liquidation.  PSTH has a SPAC completion deadline of approximately July 24, but has already qualified for a six month extension thanks to previously announcing a combination with Universal Music Group.

However, Ackman doesn’t have to extend. Depending on what happens in the next three months, he could choose to liquidate in July instead.

As a result of today’s announcement, we should probably expect a new amended S-1 soon from SPARC Holdings since the NYSE rule proposal is no longer holding up SEC review.  It’s also not holding up Ackman anymore either.  Perhaps we get some more news from the PSTH camp too.

If you’d like to review the SPARC structure, you can find a summary HERE.

 

 

Recent Posts
by Nicholas Alan Clayton on 2024-04-18 at 11:50am

AGBA (NASDAQ:AGBA) stock is up over +90% this morning following a +211% premarket spike on news it has signed a definitive agreement to combine with social streaming video platform Triller. AGBA, the company itself, was formed by the $555 million combination between a SPAC of the same name and TAG Companies, a financial services firm...

by Nicholas Alan Clayton on 2024-04-18 at 7:57am

At the SPAC of Dawn Since closing its combination with DHC last month, AI customer engagement firm BEN (NASDAQ:BNAI) has rolled out new partnerships with call center and healthcare clients. And, while it faces a fair bit of competition in the chatbot realm, several high-profile institutions have demonstrated that creating one that provides useful services...

by Nicholas Alan Clayton on 2024-04-17 at 3:05pm

Blue Ocean (NASDAQ:BOCN) provided significantly more texture today in the presentation for its $275 million combination with Asian digital media group TNL Mediagene, which it expects to hit profitability in the second half of the year despite a slight shakeup in financing for the transaction. The first big update in the first investor deck is...

by Nicholas Alan Clayton on 2024-04-17 at 8:13am

At the SPAC of Dawn A brand new market may have just opened up for space de-SPACs as NASA administrator Bill Nelson announced a shift in the agency’s $11 billion program for a mission to return samples from Mars. Rather than rely on the agency’s internal technologies that would be predicted to get a sample...

by Nicholas Alan Clayton on 2024-04-16 at 11:33am

Overall deal flow between SPACs and biotech firms has slowed over the last year, but some pending FDA changes could breathe new life into particular business models within the space. In particular, the FDA has asked Congress as part of its 2025 Legislative Proposals to eliminate the interchangeability designation for biosimilar medications, claiming the existing...

logo

Copyright © 2023 SPACInsider, Inc. All Rights Reserved